Meningococcal polysaccharide–protein conjugate vaccines

Do CD1-Restricted T Cells Contribute to Antibody-Mediated Immunity againstMycobacterium tuberculosis?

“…In this regard, the difficulties encountered with the development of meningococcal polysaccharide vaccines (34,73), especially to serogroup B (34), and the encouraging breakthrough made in recent years with the serogroup C meningococcal vaccine (73) highlight the importance of choosing a suitable Ag(s) for vaccine development.…”

The First Case of Neisseria meningitidis Serogrup X Meningitis in Turkey

“…Biochemical findings were normal except for high blood urea nitrogen (50mg/dl) and creatinine (2.15 mg/dl). White blood cell count (WBC) was 3900/mm 3 , erythrocyte sedimentation rate (ESR) was 5mm/hour; on the next day, the WBC increased to 28.000/mm 3 , the ESR to 65mm/hour. His headache intensified and disseminated petechial eruptions appeared on his legs and chest (Figure1).…”

Update on the Use of Quadrivalent Conjugate Meningococcal Vaccines

“…(14) It would be difficult to conduct efficacy and effectiveness studies because of the relative rarity of meningococcal disease. The immunogenicity outcomes that are most commonly used are serum bactericidal antibody (SBA) levels using either human or rabbit serum as a source of complement, and enzyme linked immunosorbent assays (ELISA).…”